Agoracom Blog Home

Posts Tagged ‘CSE’

Kontrol $KNR $KNR.ca $KNR.c $KNRLF Enters into Exclusive Distribution Agreement with United Safety and Survivability Corporation for BioCloud Technology Distribution in North America, Australia and New Zealand $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:21 AM on Tuesday, December 1st, 2020
kontrol-logo
  • Entered into an exclusive Distribution Agreement with United Safety and Survivability Corporation
  • Under the terms of the agreement, the exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America, Australia, and New Zealand.
  • The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes.

TORONTO, ON / December 1, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that it has entered into an exclusive Distribution Agreement with United Safety and Survivability Corporation (“United Safety”).

“We are pleased to enter into this agreement with United Safety as we specifically target the important sector of ground transportation with an established and successful global distribution partner,” says Paul Ghezzi, CEO Kontrol. “The United Safety team shares our passion and commitment for creating safe spaces for all.”

Under the terms of the agreement, the exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America, Australia, and New Zealand. The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes.

Joseph Mirabile, CEO of United Safety says, “United Safety and Survivability Corporation is committed to delivering the most innovative and reliable solutions that our customers can trust to protect life and property. We are very excited to be sharing the Kontrol BioCloud technology with all of our customers. We see interest and demand for this innovative technology, which can help create safer spaces and help our customers solve many of the challenges they are facing in relation to the impact COVID-19 has on their business.”

About United Safety & Survivability Corporation

United Safety and Survivability Corporation is committed to delivering the most innovative and reliable safety and survivability solutions that our customers can trust to protect life and property. As a global leader in the design and engineering of world-class safety, survivability and technology solutions across a variety of industries and categories, our portfolio of products includes seating for commercial buses, fire trucks, ambulances, military vehicles, motor coaches, rail cars and locomotives. We design and build specialty soldier survivability systems for military vehicles and our revolutionary fire suppression systems are used in school buses, public transit, heavy machinery and more. Our portfolio of products includes Active Air Purification and AEGIS® Microbial Surface Treatment that help to protect the public and operators by eliminating bacteria and viruses from air and surfaces.

www.unitedsafetycorporation.com

About Kontrol BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at: www.sedar.com

For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.,
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloudTM Analyzer (BioCloudTM) are subject to the risk that the Kontrol BioCloudTM Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications. Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Reports Third Quarter 2020 Results $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 4:19 PM on Monday, November 30th, 2020
kontrol-logo

  • Q3 2020 revenue increased by 32% over Q2 2020
  • Adjusted EBITDA of $848,249 reported for Q3 2020 compared to $206,435 for the same quarter in the prior year
  • Adjusted EBITDA for the nine months ended September 30, 2020 was $1,492,252 compared to $707,263 for the same period in the prior year
  • Revenue for Q3 2020 was $3.01 million down from $3.27 million in Q3 2019, and year to date totalled $8.05 million down from $10.86 million for the comparative period in the prior year

TORONTO, ON / November 30, 2020 / Kontrol Energy Corp. (CSE:KNR, OTCQB:KNRLF, FSE:1K8) (“Kontrol” or “Company”) a leader smart buildings and smart cities through IoT, Cloud and SaaS technology announces its financial results for the nine months ended September 30, 2020.

A complete set of Financial Statements and Management’s Discussion & Analysis will be filed on SEDAR (www.sedar.com) on November 30, 2020. A call to discuss the financial results has been scheduled for Monday, November 30, 2020 at 4:30pm (EST).

“We had a significant improvement in the third quarter against an ongoing challenging backdrop as businesses continue to deal with the impact of COVID-19,” says Paul Ghezzi, CEO. “In addition, the Company achieved further advancements in the development of the Kontrol BioCloudTM viral and air-borne pathogen detection technology during the third quarter of 2020.”

Highlights

  • Q3 2020 revenue increased by 32% over Q2 2020
  • Adjusted EBITDA of $848,249 reported for Q3 2020 compared to $206,435 for the same quarter in the prior year
  • Adjusted EBITDA for the nine months ended September 30, 2020 was $1,492,252 compared to $707,263 for the same period in the prior year
  • Revenue for Q3 2020 was $3.01 million down from $3.27 million in Q3 2019, and year to date totalled $8.05 million down from $10.86 million for the comparative period in the prior year
  • Cash flow from operating activities for the nine months ended September 30, 2020 was $531,675
  • On August 1, 2020 Kontrol completed the acquisition of New Found Air (“NFA”), a building energy solutions business
  • Capital management activities during Q3 and subsequent to the quarter have strengthened the balance sheet (see below)
  • BioCloudTM product development continued at a rapid pace through the third quarter (see below)

Active capital management and balance sheet strengthening

Options and warrants converted into common shares:

  • Approximately 4.2 million options and warrants were exercised in Q3 and up to date of this press release (average exercise price was $0.73 per share)
  • Proceeds from options exercise
    • Q3 2020: $653,000
    • October 1, 2020 to date of this press release: $224,000
  • Proceeds from warrants exercise
    • Q3 2020: $1,404,000
    • October 1, 2020 to date of this press release: $805,000

Convertible debentures converted into common shares

  • Approximately 3.2 million common shares were issued in connection with convertible debenture conversions to common shares in Q3 and up to date of this press release
  • 2024 convertible debenture conversion to common shares
    • Q3 2020: $866,000
    • October 1, 2020 to date of this press release: $143,000
    • Conversion price was $0.80 per share
  • 2023 convertible debenture conversion to common shares
    • Q3 2020: $0
    • October 1, 2020 to date of this press release: $988,000
    • Conversion price was $0.50 per share

2020 debenture and 2022 debenture

  • The Company announced a non-brokered private placement for gross proceeds of $5,800,000, allowing existing holders of 2020 debentures to exchange for 2022 debentures maturing on October 31, 2022
  • Subscription proceeds are currently being processed in connection with the new 2022 debenture and the extension will be reflected in Q4 and the Company’s December 31, 2020 annual financial statements

Cash position

  • The Company’s cash balance as at September 30, 2020 was $3,065,995 compared to $644,313 as at December 31, 2019 for a net cash increase of $2,421,682. While proceeds from options and warrants exercise were significant contributors to the net cash increase, management is equally pleased with cash flow that was generated from operating activities of $531,675 for the year to date period.
  • The Company’s cash balance on day of this press release was approximately $3,800,000.

Q3 2020 and Year to Date Financial Summary

       
Financial Results Three months ended  Nine months ended 
(unaudited) Sept 30, 2020  Sept 30, 2019  Sept 30, 2020  Sept 30, 2019 
Revenue $3,012,386  $3,266,270  $8,047,477  $10,856,816 
Gross profit $1,601,830  $1,709,248  $4,315,650  $5,465,008 
Net loss $(193,541) $(692,175) $(1,305,904) $(1,968,653)
Basic and Diluted EPS $(0.01) $(0.02) $(0.04) $(0.07)
                 
Add for adjusted EBITDA reconciliation:                
Amort. and depreciation $538,159  $486,187  $1,490,017  $1,355,686 
Finance expense $250,346  $272,458  $816,742  $779,277 
Share based compensation $227,274  $72,686  $455,386  $462,576 
Acquisition related expenses $26,011  $67,279  $36,011  $78,377 
Adjusted EBITDA* $848,249  $206,435  $1,492,252  $707,263 
                 

Kontrol BioCloudTM

The Company has made important progress on its BioCloud TM technology including the receipt of various certifications and filing of trademarks and patents. As part of our ongoing strategy to manage capital and accelerate towards the production of BioCloud the Company is working with various third-party suppliers and contract manufacturers. BioCloud TM product development costs incurred for the current year to date period and up to the time of this press release was approximately $615,000. The Company’s cash position and resources available are sufficient to commence the production of BioCloud TM.

* Adjusted EBITDA is a non-IRFS financial measure. The Company defines Adjusted EBITDA as net income or loss before interest, income taxes, amortization, and depreciation, share based compensation, and acquisition related expenses.

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com

The future of live sport – how brands can make an impact with new digital possibilities #AR – SPONSOR: Imagine AR $IP.ca $IPNFF $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 4:04 PM on Monday, November 30th, 2020

SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. ImagineAR and NFL Alumni Academy recently signed a 5 year partnership agreement. The company was selected by Canadian pharmacy chain Shoppers Drug Mart to deliver Immersive AR Conference Experience and if that’s not enough, Imagine AR just signed its second La Liga team to provide AR experiences for fans.  Learn More.

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

The future of live sport – how brands can make an impact with new digital possibilities

  • We’ve seen the already growing appetite for virtual event counterparts accelerate during the lockdown period.
  • Our consumer research found that football fans in the UK are now three times more likely to find the prospect of augmented reality (AR) replays and stats exciting, with younger fans more likely to use these technologies in the near future.

By: Mark Melling, Verizon Media

Digital fan experiences like the NFL’s ‘Watch Together’ synchronised livestream are reinventing the way in which consumers enjoy live sports content.

The absence of live sport throughout the COVID-19 pandemic has been felt strongly by fans like me across the globe. From the pre-game rituals, half-time debrief with friends and the atmosphere within the stadium, fans have been missing out on the communal and experience-led aspect of a physical game.

In response to this, we’ve adapted our strategy and looked at new and innovative ways we can elevate the sports fan experience as well as focusing on the entertainment sector more broadly.

We’ve seen the already growing appetite for virtual event counterparts accelerate during the lockdown period. Our consumer research found that football fans in the UK are now three times more likely to find the prospect of augmented reality (AR) replays and stats exciting, with younger fans more likely to use these technologies in the near future.*

This demonstrates how fans are starting to see the value these technologies bring, and so will be more likely to continue using them to enhance the digital experience – even when live sporting events start-up again.

More broadly, the expectation for consumers is that most offline events will have some sort of digital twin and be augmented by tech in some way. We’re already starting to see this amongst the younger generation, with 83% of UK millennials claiming they expect their digital experiences and interactions with brands online to be seamless, innovative, and to enhance what’s happening in the real world.*

The convergence of online and offline

These sorts of insights have been integral in driving our strategy and the platforms we use moving forward – highlighting the importance of exploring the convergence of online and offline.

As part of this, it’s been important for us to consider two key streams: live events with virtual integrations and virtual events with live integrations. The former will be vital for sport as virtual elements can be incorporated to enhance the offline experience.

For example, better quality video streaming, immersive experiences and real-time virtual reality (VR) and AR overlays that will allow viewers to watch the game from multiple angles – including cameras on the players and referees, so that fans can get a point of view shot and feel more involved in the action.

COVID-19 has been instrumental in accelerating demand for these types of experiences. And technology can help to create communal experiences for viewers, even when they are unable to attend the physical venue to watch the game with friends and family under current lockdown restrictions.

As a result, everyone working within the sports industry – from production and distribution to branding and marketing – has had to adjust their strategy and adapt to bringing digital experiences to the forefront. Much of this technology was already in the pipeline but the global pandemic has accelerated plans due to the need to shift to digital overnight.

NFL partnership: ‘Watch Together’

One of the ways we helped to improve the digital fan experience within the sports industry was through our recent partnership with the NFL to launch ‘Watch Together’.

The new platform consists of a co-viewing experience that enables fans to video chat on their phones whilst watching live games in the Yahoo Sports App in the US. Watch Together for NFL Live on Yahoo Sports will give fans the ability to invite up to three family and friends to watch live local and primetime NFL games on their phones through a synchronised livestream, creating an interactive, virtual experience that lets viewers feel like they are watching the game together. 

On top of this, the new Yahoo Sports game centre experience offers fans the ability to see graphical replays of key NFL game plays in near real-time using its proprietary Next Gen Stats player tracking data. The NFL is the first launch partner for Watch Together, but it could easily be replicated across the whole sport sector and demonstrates the digital capabilities for consuming live events.

These viewing experiences will be game-changers moving forward, even post-pandemic, and will more intrinsically link the offline and online element of live events. This is an incredible opportunity for brands to test themselves. And marketers should be thinking about their engagement strategies now to establish themselves in this evolving world, taking hold of the unique digital opportunities that are arising. 

Supercharging the experience with 5G

This is also where 5G can make a real impact – supercharging the fan experience through rich, real-time and immersive experiences. It will enhance existing technologies and help to cater for the increased demand for online events, while also elevating offline experiences in the future.

For example, e-commerce, social interaction and video replays in between games are all currently available but can be heightened, personalised and delivered in real-time at scale through the connectivity that 5G will enable.

Brands can tap into these opportunities by thinking creatively about ways to bring together the online and offline elements in a meaningful way that will connect with consumers. For live sports – and indeed live entertainment events more broadly – we can expect interactive and immersive experiences to become the norm, with fans looking for new ways to watch the game from their homes.

Brands that do not adapt and help to drive these unique experiences risk being left behind as we hurtle towards a more digitised future.

Source: https://www.warc.com/newsandopinion/opinion/the-future-of-live-sport–how-brands-can-make-an-impact-with-new-digital-possibilities/3901

UK to invest in #AI and #cyber as part of major #defense spending hike – SPONSOR: KWESST Micro Systems $KWE.ca $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 3:39 PM on Monday, November 30th, 2020

SPONSOR POST:

WHY KWESST? HERE’S SOME GREAT REASONS

1.   KWESST is a leader in defensive technologies that increase the capabilities of soldiers, including
those of NATO and its allies

2.  These technologies make a critical difference to soldier safety and effectiveness

3.  The Leadership team experience spans decades and hundreds of millions of dollars in military and homeland security contracts.

4.  KWESST develops next-generation systems for forces around the world, with a particular focus on special forces among NATO countries and their allies.

Image-1

5.  KWESST partners with globally recognized equipment manufacturers to integrate its systems into
their solutions to create high value-add products for global customers.

Image-2

UK to invest in AI and cyber as part of major defense spending hike

By: Natasha Lomas

The UK has announced a massive boost in defense spending — £16.5 billion ($21.8BN) over four years, the biggest such spending bump for 30 years — in what prime minister Boris Johnson has described as a “once in a generation modernization” of the UK’s armed forces and “the end of the era of retreat” on funding for defense.

Overall the UK prime minister said the spending hike will create 40,000 jobs, adding that it will cement the country’s position as the biggest military defense spender in Europe and the second largest in NATO after the US.

Johnson said the focus for investment will be on cutting edge technologies that can “revolutionize” warfare — implying a major role for artificial intelligence and sensor-laden connected hardware in “forging our military assets into a single network designed to overcome the enemy”, as he put it in a statement to parliament, setting out the first conclusions from an the (ongoing) review of security, defense, development and foreign policy.

“A soldier in hostile territory will be alerted to a distant ambush by sensors or satellites or drones instantly transmitting a warning using artificial intelligence to device the optimal response and offering an array of options — from summoning an air strike to ordering a swarm attack by drones, or paralyzing the enemy with cyber weapons,” Johnson told the House of Commons today, speaking via video conference as he continues to self isolate following a coronavirus contact.

“New advances will surmount the old limits of logistics,” he went on, fleshing out the rational for spending on upgrading military technology. “Our warships and combat vehicles will carry directed energy weapons — destroying targets with inexhaustible lasers. And for them the phrase out of ammunition will become redundant.”

“Nations are racing to master this new doctrine of warfare and our investment is designed to place Britain among the winners,” he added.

The review sets out at least £1.5BN extra — and £5.8BN total — spending on military R&D which Johnson said would be “designed to master the new technologies of warfare”.

There will also be a new R&D center set up with a dedicated focus on artificial intelligence, he added.

An RAF Space Command center is also in the works — with the aim of launching British satellites including the UK’s first rocket from Scotland in 2022.

While the airforce will get new fighter system that Johnson specified will incorporate AI and drone technology.

He also confirmed the existence of a National Cyber Force — a joint unit consisting of personnel from the UK’s intelligence agencies and military personnel which runs cyberops targeting terrorism, organized crime and hostile foreign state actors.

He suggested the hike in military spending on emerging technologies will filter down into wider societal tech gains, telling MPs: “The returns will go far beyond our armed forces — from aerospace to autonomous vehicles — these technologies have a vast array of civilian applications, opening up new vistas of economic progress.”

Responding to Johnson’s statement, the leader of the opposition, Keir Starmer, welcomed the announcement of increased spending for defense and the armed forces — but accused the government of issuing another “press release without a strategy” — pointing out that successive Conservative governments have eroded defense spending over the past ten years.

“This is a spending announcement without a strategy. The government has yet again pushed back vital parts of the integrated review and there’s no clarity over the government’s strategic priorities,” said Starmer, going on to query how the spending hike would be funded, given the economic crunch facing the UK as a result of the pandemic — asking whether it will require tax rises or cuts to public spending elsewhere, such as to the international development budget.

Starmer also raised the awkward matter of the Russia report — wondering why Johnson’s government has not acted on the “urgent” national security risks identified there.

The report, by parliament’s intelligence and security committee, found the UK lacks a comprehensive and cohesive strategy to respond to the cyber threat posed by Russia and other hostile states that are deploying online disinformation and influence ops to target democratic institutions and values.

It also sounded the alarm about how much Russian money is finding its way into UK political party coffers.

“The prime minister speaks of tackling global security threats, improving cyber capability — and that is all welcome, and we welcome it — but four months after the intelligence and security committee published its report concluding that Russia posed… an immediate and urgent threat to our national security,” noted Starmer.

Replying, Johnson dodged all Starmer’s questions — branding his criticisms “humbug [that] takes the cake” and opting to attack the Labour leader for having served under the party’s former leader, Jeremy Corbyn, who did not support increasing UK defense spending.

Source: https://techcrunch.com/2020/11/19/uk-to-invest-in-ai-and-cyber-as-part-of-major-defense-spending-hike/

AGORACOM Small Cap 60: Innocan $INNO.ca #CBD Products Ready For Launch With Positive Clinical Test Results $CGC.ca TLRY $VFF.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 2:33 PM on Monday, November 30th, 2020
Innocan-Blog

Innocan (INNO:CSE) has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when Innocan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Files Patent Applications With the U.S. Patent and Trademark Office and the Canadian Intellectual Property Office for Its #Biocloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:15 AM on Monday, November 30th, 2020
kontrol-logo
  • Announced that as a follow up to its press release dated September 23rd, 2020, the Company has filed four patent applications for its BioCloudTM Technology.
  • Four patent applications have been filed, three with the U.S. Patent and Trademark Office and one with the Canadian Intellectual Property Office : SYSTEM AND METHOD FOR DETECTING AIRBORNE PATHOGENS

TORONTO, ON / November 30, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company”) a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology is pleased to announce that as a follow up to its press release dated September 23rd, 2020, the Company has filed four patent applications for its BioCloudTM Technology.

Four patent applications have been filed, three with the U.S. Patent and Trademark Office and one with the Canadian Intellectual Property Office : SYSTEM AND METHOD FOR DETECTING AIRBORNE PATHOGENS.

“These patent applications address key attributes of our technology, which utilizes a combination of continuous air quality monitoring and a proprietary detection chamber to target and identify airborne pathogens to help create safer spaces,” says Paul Ghezzi, CEO Kontrol. “We are very proud of our team and the milestone this represents. Innovation is at the core of our operations and we continue to execute on our plans.”

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware and service solutions to its customers to improve energy management, air quality and deliver continuous emission monitoring.

Additional information about Kontrol Energy Corp. and BioCloud can be found on its websites at www.kontrolenergy.com and www.kontrolbiocloud.com, and by reviewing its profile on SEDAR at www.sedar.com


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Empower Clinics $CBDT.ca $EPWCF Signs North American Distribution Agreement with API Pharma USA For FDA EUA #COVID-Rapid Antigen & Antibody Tests. Supported Three Months of Clinical Trials $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:21 AM on Monday, November 30th, 2020
  • Announce the North American Re-Seller & Distribution Agreement with API Pharma (“API”) for its FDA EUA submitted Rapid Antigen Test and Rapid Antibody Test.
  • Empower’s KAI Medical Laboratory provided API significant scientific data through three months of clinical trials.
  • As a result, Empower and API are now able to sell these products with confidence, on an unlimited basis, to its customers and prospective customers nationwide in the United States and in European countries supporting CE mark approval.

VANCOUVER, BC / November 30, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the Southwest United States, a telemedicine platform and medical diagnostics laboratory is pleased to announce the North American Re-Seller & Distribution Agreement with API Pharma (“API”) for its FDA EUA submitted Rapid Antigen Test and Rapid Antibody Test.

Empower’s KAI Medical Laboratory (“KAI”) provided API significant scientific data through three months of clinical trials. As a result, Empower and API are now able to sell these products with confidence, on an unlimited basis, to its customers and prospective customers nationwide in the United States and in European countries supporting CE mark approval.

Furthermore, Empower and KAI are providing API with support for its Health Canada submission for its Rapid Antigen Detection Test (“RADT”) (COVID-19 Application For Authorization If Import Or Sale Of Medical Devices). Empower will have Canadian distribution rights upon Health Canada approval.

Steven McAuley, Chairman and CEO of Empower stated “Our society is experiencing unprecedented changes that are affecting how we go back to work, how we travel and how we might gain permission to interact with others. Testing protocols and testing products are becoming a part of our daily lives, and there are key differences between PCR, antigen and antibody tests. They are all important, irrespective of how potential vaccines come to market. Our company is leading and positioned to provide all of these important tests to the markets we serve.”

The global COVID-19 diagnostics market size is valued at USD 19.8 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 3.1% from 2021 to 2027. These tests are critical in the management of the ongoing COVID-19 pandemic for accurate diagnosis as well as for tackling the spread of the infection (https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market)

WHAT IS A RAPID ANTIGEN DETECTION TEST (RADT)?

An RADT is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence or absence of an antigen. This distinguishes it from other medical tests that detect antibodies or nucleic acid, of either laboratory or point of care types.

WHAT IS AN ANTIBODY TEST?

An antibody test, also known as a serology test, looks for specific antibodies in your blood. This test is useful because it shows if someone has had the infection in the past, even if you had only mild symptoms.

One inherent advantage of an antigen test over an antibody test is that it can take time for the immune system to develop antibodies after infection begins, but the foreign antigen is present within a preliminary incubation period of five days or less.

GOVERNMENT OF CANADA – RADT’s WILL HAVE AN IMPORTANT ROLE TO PLAY

The Government of Canada website for the use of RADT stated the following”

“Potential characteristics of these tests (faster turnaround time, lower per-test cost, ability to do the test in a setting by non-professionals on a more frequent basis, amongst others) suggest that they will have an important role to play in the next phase of the response. It is important for the public health, infectious diseases experts and laboratory communities to identify the scenarios where the use of RADTs may further strengthen the public health response by expanding access to testing”

(https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-detection-tests.html)

API PHARMA – NO CHOICE BUT TO RAPID TEST

Rapid testing is critical to any strategy for containing COVID-19. It helps determine where the virus is spreading, who has immunity and how widely the virus has spread.

The COVID-Rapid Antigen Test determines who has the virus at present and is likely to be contagious. With >99% sensitivity for those who are contagious, the rapid results allow healthcare providers to make quick and accurate medical decisions.

The COVID-Rapid Antibody Test, which screens blood for antibodies, can allow hospitals and workplaces to identify people who were infected and may have already developed immunity. Studies have shown that one-third to one-half of those infected with COVID-19 are asymptomatic. As a result, serology tests help determine who can lead the way back to reopen businesses and work on the front lines of health care.

The COVID-Rapid line of tests are accurate and affordable so it can be used for testing large populations. America has no choice but to rapid test for COVID-19 so that governments, schools, and workplaces can test large groups of individuals, not just those who present with symptoms.

API PHARMA RADT DEMONSTRATED HIGHLY EFFECTIVE ON 3 CONTINENTS

API Pharma’s COVID-Rapid Antigen test has been tested and demonstrated to be highly effective on three continents. This is important as it demonstrates all the different strains of the virus will respond equally to the rapid antigen test. Clinical studies were carried out specifically in China, the United States and Poland.

PARTNERSHIP FURTHER SOLIDIFIES KAI MEDICAL FOOTHOLD IN COVID-19 TESTING SPACE

The clinical trials of API products performed a variety of studies including the precision, accuracy, sensitivity, and interfering substances, as well as, the efficacy of operators to perform the test accurately. These studies ensure that API-products meet industry standards for testing and will accurately identify COVID-19 positives as well as COVID-19 negatives.

Because of API’s focus on Rapid, Point-of-Care testing for both antibodies and antigens, in addition to Kai Medical’s extraordinary capacity to handle industry-standard turnaround times for RT-PCR testing, this partnership further solidifies Kai Medical’s foothold in the COVID-19 testing space.

Yoshi Tyler, President of KAI Medical Laboratory stated “We anticipate that, moving forward, there will be a focus on much more rapid and accurate point-of-care testing, in order to return to everyday life. Like the virus, our testing strategies must be adaptable. As we move forward, we continue to prioritize the best and most efficacious testing strategies.”

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

ABOUT API PHARMA

API Pharma (API) is an industry leader in designing and distributing rapid tests for a range of viruses and diseases, including rotovirus, influenza, hepatitis, herpes, HIV, and others.

API’s rapid COVID-19 test is nearly as simple as a home pregnancy test, requiring only a few drops of blood from a finger stick and a drop of reagent. Results are available in under 20 minutes and are simple to interpret: one line means negative, two lines means positive. The test has 97% sensitivity and 97% specificity, and API’s long experience with rapid tests makes it a reliable provider. API currently has approval to provide test kits to medical facilities in the U.S. and expects to have FDA approval for home use soon. The test is already in use in Europe.

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ABOUT Kai Medical Laboratory

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

VIDEO – Loop Insights $MTRX.ca $RACMF Talks To Shareholders Live From T-Mobile Arena #NCAA #VegasBubble $AT.ca $QTRH.ca $SNSR $BSQR $PTS.ca

Posted by AGORACOM-JC at 12:56 AM on Saturday, November 28th, 2020
https://miro.medium.com/max/3150/1*f9msDHyceA_TbRM30jQhsw.png

On October 8, 2020 Loop Insights (MTRX:TSXV) (RACMF:OTCQB) announced it had been  “Selected as the Premier Venue Tracing and Fan Engagement Solution for NCAA College Basketball “Bubble” in Las Vegas”.

In that press release, MTRX CEO Rob Anson stated:

“Interest in Loop’s integrated contactless platform by NCAA Division I conferences, schools, and now events have been significant over the past couple of months as they desperately search for best of breed solutions that will allow them to safely restart operations and generate revenue. Being selected for the Vegas bubble is more validation and another major opportunity for Loop to showcase our contactless capabilities on a large-scale project with a global audience. With this agreement, it is fair to say that Loop continues to be the leader in live venue contactless technology.”

Fast forward to today and investors get a chance to see Anson on the floor of T-Mobile Arena answering shareholder questions and providing them with further insight into where the Company is going with its integrated contactless platform …. and he does it all while avoiding getting dunked on by the Washington Huskies Women’s Basketball Team who were practicing at the exact same time 🙂

If you missed the live version, don’t miss this on demand version.

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

AGORACOM Small Cap 60: Innocan $INNO.ca Developing The Pharmaceutical Guided Missile To Defeat #Coronavirus Lung Infections $CGC.ca $APHA $OVAT.ca $KHRN.ca

Posted by AGORACOM-JC at 12:53 PM on Friday, November 27th, 2020
Innocan-Blog

Innocan Pharma Corporation (INNO:CSE) (IP4:FSE) has 3 fully operating divisions to address the market for Cannabis products.  As a Cannabis investor, why limit yourself to a Company with just one specialty, when InnoCan offers you exposure to both the exploding world of cannabis pharma, as well as, a portfolio of patent-pending and launch ready consumer health products.

The Top 5 Industries That Will Benefit the Most From Augmented Reality #AR – SPONSOR: Imagine AR $IP.ca $IPNFF $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 11:19 AM on Friday, November 27th, 2020

SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. ImagineAR and NFL Alumni Academy recently signed a 5 year partnership agreement. The company was selected by Canadian pharmacy chain Shoppers Drug Mart to deliver Immersive AR Conference Experience and if that’s not enough, Imagine AR just signed its second La Liga team to provide AR experiences for fans.  Learn More.

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

The Top 5 Industries That Will Benefit the Most From Augmented Reality

By Roger Bishop

Augmented reality and virtual reality get most of their fame from the videogame industry, but the more practical uses are becoming more and more utilized across almost every major industry in the United States. Virtual reality is a complete sensical change from an individual’s given surrounding, and generally involves putting on some kind of encompassing headgear that shuts out what is actually around the users. Augmented reality, on the other hand, utilizes technology created to interact with reality, “augmenting” what is actually already there. One of the simplest examples would be a photo filter on your phone that adds sunglasses to whomever you’re taking a picture of. This article will take a look at 5 industries that can (or are already) benefit from evolutions in Augmented Reality (AR).

Construction

Augmented reality in construction can serve a number of purposes, with two of the most important being in safety and saving money. The U.S. construction business generates more than $1.2 trillion every year, and employs more than 7 million Americans. With that many players in the game, even pennies saved here and there can add up quickly. Recent trends, mainly caused by regulation and availability from the public sector, have shown lacks of productivity in the construction industry caused by poor design, poor management, and lacks in development.

AR models can help identify design issues before building starts, saving time and money, and can also help during construction, showing precise directions regarding certain installations and trades. AR is also being heavily utilized in training, and the construction sector is following suit.

Rehabilitation

The uses for AR in healthcare are aplenty, and growing by the day; however, most uses are still in a “clinical trials” phase to determine what is working and what is not. When it comes to rehab, though, AR is already a proven means of increasing therapy outputs. For PTSD, in particular, augmented reality programs can help patients take very small “doses” of whatever causes their trauma in an attempt to slowly ween them off the fear. For soldiers, this can mean subtly adapting to loud noises in a controlled environment until those noises and interruptions no longer act as triggers for past traumatic experiences.

Nursing

For nursing, training is a part of the weekly grind. From cultural diversity training to new procedures, nurses are permanently learning, and AR is giving them a chance to do so in a much more effective manner. Smart glasses are a new technology that allow nurses to work on a patient while having information about the procedure appear, literally, right in front of their eyes on a glass screen that is something out of a James Bond film. This AR training also allows for nurses to get more experience without actually working on a sick individual.

Education

As a whole, the education sector serves to benefit greatly from AR as well. For trade schools, the possibilities are almost endless, but even general, every day education is enacting some forms of augmented reality into their curriculums. There are many AR apps being tailored for education, and as long as schools can provide equal means of utilizing these technologies among all students, the interactive aspects are expected to help students stay focused, as well.

Video Games

Of course, video games are still the industry that most of us first saw AR in action, with the Pokemon Go’s of the world, and the industry certainly isn’t shying away from AR now that it’s becoming popular in other sectors of business. Global augmented reality is the “new future” and allows gamers to, literally, see things that only exist digitally, all across the actual world we live in and breath on every day.

Source: https://www.universenewsnetwork.com/2020/11/27/the-top-5-industries-that-will-benefit-the-most-from-augmented-reality/